Audentes Therapeutics. Letter to the MTM disease community. https://myotubulartrust.org/audentes-therapeutics-letter-23-june-2020/ (last accessed June28, 2020).
2.
MackDL, PoulardK, GoddardMA, et al.Systemic AAV8-mediated gene therapy drives whole-body correction of myotubular myopathy in dogs. Mol Ther, 2017; 25:839–854.
3.
PhillipsA, BelleA, GuoJ, et al.Nonhuman primate safety and potency of an AAV vector for XLMTM produced by transient transfection at 500L. American Society for Gene and Cell Therapy Annual Meeting, Washington, D.C., 2017.
4.
MendellJR, Al-ZaidyS, ShellR, et al.Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med, 2017; 377:1713–1722.
5.
FlotteTR. Revisiting the “new” inflammatory toxicities of adeno-associated virus vectors. Hum Gene Ther, 2020; 31:398–399.
6.
HindererC, KatzN, BuzaEL, et al.Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther, 2018; 29:285–298.
7.
SomanathanS, CalcedoR, WilsonJM. Adenovirus–antibody complexes contributed to lethal systemic inflammation in a gene therapy trial. Mol Ther, 2020; 28:784–793.
